May 7th 2024
With the clearance of an investigational new drug application for BTX-9341 from the FDA, a phase 1 trial will evaluate the agent in HR-positive/HER2-negative breast cancer.
Patient, Provider and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of HR+/HER2- Breast Cancer
View More
Show Me Your Care Plan: Nursing Considerations for Managing Breast Cancer Patients
View More
Community Practice Connections™: The Newest Frontier in HR+ Breast Cancer—Targeting ESR1 Mutations with Next-Generation Endocrine Therapy
View More
Clinical Case Vignette Series™: 40th Annual Miami Breast Cancer Conference®
View More
Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician
View More
HER2+ Breast Cancer Tumor Board: Navigating Current and Evolving Strategies from Early Stages to Metastases
View More
Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure
View More
Show Me the Data®: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
23rd Annual International Congress on the Future of Breast Cancer® West
July 12-13, 2024
Register Now!
23rd Annual International Congress on the Future of Breast Cancer® East
July 19-20, 2024
Register Now!
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Community Practice Connections™: Leveraging Multidisciplinary Teams in Early-Stage Breast Cancer When the Goal Is Cure
View More
Community Practice Connections®: Evaluating the Evolving Treatment Landscape for mHR+ Breast Cancer-How to Personalize Care and Improve Patient Outcomes
View More
Community Practice Connections™: 22nd Annual International Congress on the Future of Breast Cancer®
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
22nd Annual School of Breast Oncology
November 7-9, 2024
Register Now!
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Emerging Treatments and Evolving Paradigms in HER2-Low Breast Cancer
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
Clinical Vignettes™: The Experts Explain How They Integrate PET Imaging into Metastatic HR+ Breast Cancer Care Settings
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
School of Breast Oncology® Live Video Webcast: Clinical Updates from San Antonio
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
The Results From a Phase II Study Analyzing First-Line Eribulin Mesylate
January 7th 2014Kristi McIntyre, MD, a physician with Texas Oncology, discusses the results of a phase II, multicenter, single-arm study looking at eribulin mesylate as first-line therapy for locally recurrent or metastatic HER2-negative breast cancer.
Watch
An Analysis of the PALOMA-3 Trial
January 3rd 2014Nicholas Turner, PhD, consultant medical oncologist, The Royal Marsden Hospital, London, discusses the PALOMA-3 trial, which studied palbociclib combined with fulvestrant for the treatment of patients with hormone receptor-positive, HER2-negative metastatic breast cancer after endocrine failure.
Watch
Neoadjuvant Carboplatin Increases pCR Rates in TNBC
December 16th 2013Study investigators reported at the 2013 San Antonio Breast Cancer Symposium that the addition of carboplatin to standard neoadjuvant chemotherapy increased pathologic complete response (pCR) rates in patients with triple-negative breast cancer (TNBC).
Read More
Survival Not Extended by Locoregional Treatment of MBC
December 16th 2013According to the results of a prospective, randomized, controlled trial, in women with metastatic breast cancer that responds to frontline chemotherapy, locoregional treatment (LRT) of the primary tumor and axillary nodes does not produce an increase in overall survival (OS).
Read More
PIK3CA Mutation Predicts Resistance to HER2-Targeted Therapy
December 16th 2013Findings reported at the 2013 San Antonio Breast Cancer Symposium showed that PIK3CA-mutated tumors in patients with HER2-positive (HER+) breast cancer (BC) are associated with a much lower rate of pathological complete response (pCR).
Read More
AI-Associated Joint Pain Curtailed by Exercise Program
December 16th 2013A new study reported at the 2013 San Antonio Breast Cancer Symposium shows that a prescribed exercise program reduces joint pain in breast cancer survivors taking aromatase inhibitors (AIs), with pain reductions observed at all levels of exercise.
Read More
Anastrozole May Prevent Some Breast Cancers
December 16th 2013According to newly reported findings from the International Breast Cancer Intervention Study II (IBIS-II), anastrozole may be a new option for primary prevention of breast cancer in postmenopausal women at high risk for the disease.
Read More
Dasatinib Doubles PFS in HER2-Negative Metastatic Breast Cancer
December 14th 2013In women with hormone receptor-positive, HER2-negative metastatic breast cancer, the addition of dasatinib to standard aromatase inhibitor therapy with letrozole doubled progression-free survival (PFS) compared with letrozole alone.
Read More
Postoperative Radiotherapy Not Necessary in All Patients
December 13th 2013If treated with hormonal therapy and considered to be at low risk for breast cancer recurrence, women aged 65 and older with hormone receptor-positive, axillary node-negative breast cancer may be able to forego radiation therapy (RT) after breast conserving surgery.
Read More
Adjuvant Bevacizumab Does Not Improve Survival in HER2-Positive Breast Cancer
December 13th 2013According to results from the large randomized BETH trial, bevacizumab did not improve invasive disease-free survival (IDFS) or overall survival (OS) when added to adjuvant therapy for HER2-positive breast cancer.
Read More
Benefits of Screening Mammography More Consistent Than Previously Thought
December 12th 2013According to an analysis of key screening studies presented at the 2013 San Antonio Breast Cancer Symposium, the benefit of screening mammography is more consistent across studies than has previously been thought.
Read More